Amgen stock holds after Q2 beat and raised 2026 outlook
Published on 08/30/2026 at 16:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. (US0311621009) finished the latest session at $432.42, with market value put at $233.78 billion as investors digested a second-quarter beat and a higher 2026 outlook. The stock closed on August 28, 2026, and the move keeps attention on earnings quality after another strong report.
Second-quarter numbers
For the quarter ended June 30, 2026, Amgen reported revenue of $10.05 billion and adjusted earnings of $6.29 per share, according to the latest earnings update summarized by market data providers. Revenue rose 9.5 percent from $9.19 billion a year earlier, while EPS beat the $5.62 consensus by $0.67.
The same update put net margin at 22.95 percent and return on equity at 124.14 percent. Those figures matter because they show the quarter was not only larger, but also highly profitable compared with the prior-year period.
Guidance is the key
Management lifted 2026 EPS guidance to $22.30-$23.50 after the second-quarter results, and analysts were clustered around $22.97 for the year. That gap is modest, but it leaves room for the market to focus on whether margins and product mix can hold up through the rest of 2026.
Amgen's shares have also outpaced the medical-biotech group this year, with one recent research roundup citing a 37 percent year-to-date gain versus 12.1 percent for the industry. The comparison is useful for investors because it shows the stock already carries a strong 2026 rerating even before the next earnings update.
Read more
Amgen earnings and guidance summary
What Amgen sells
Amgen's portfolio includes therapies such as Enbrel and Repatha, alongside newer drugs that helped lift second-quarter sales. That mix matters because the company is leaning on both established cash generators and newer growth drivers to support the 2026 profit outlook.
Stock level
At $432.42 on August 28, 2026, Amgen trades well above its 50-day moving average of $388.64 and its 200-day moving average of $364.71. The market cap of $233.78 billion and the 26.88 P/E ratio show a large-cap stock that already prices in a lot of the current earnings strength.
Fact box
Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq
Price (as of August 28, 2026, 4:00 p.m. ET): $432.42 USD
Market cap: $233.78 billion
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100, S&P 500
Next earnings date: November 2026
